Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Cendakimab (CC-93538) Formulations in Healthy Adults
NCT04373187Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- Jun 2020
- Primary completion
- May 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of cendakimab in eosinophilic esophagitis (EoE) (2 arms), sponsored by Celgene Corporation. Primary endpoints: Area Under the Curve from Time 0 to Infinity and Maximum Plasma Concentration. Started Jun 2020; status: completed.
02
Drugs
cendakimab
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on NCT04373187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04373187.